Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | June 02, 2026 | June 04, 2026 |
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Interim CFO | May 06, 2022 | May 13, 2022 |
| Enovis CORPENOV · Entity 4797 | Director | May 19, 2026 | May 22, 2026 |
| INVACARE HOLDINGS CorpIVC · Entity 86444 | Director | March 16, 2018 | March 20, 2018 |
| Option Care Health, Inc.OPCH · Entity 4126 | Director | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,045 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 21,045 F1: Restricted stock units granted on June 2, 2026. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on June 2, 2026. Price not applicable.
DENTSPLY SIRONA Inc.
Report date May 06, 2022 · Filed May 13, 2022
This filing explicitly reported no securities owned.
Enovis CORP
Report date May 19, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.001SEC Table I · non-derivative | Direct | 24,201 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 9,346 · Balance 24,201 |
INVACARE HOLDINGS Corp
Report date March 16, 2018 · Filed March 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 11,728 |
Reported balance
After 2018-03-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-03-16 · Grant · Acquired 6,708 · Balance 11,728 F1: Restricted stock units granted pursuant to the Invacare Corporation 2013 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2019. F2: Includes 5,020 previously reported restricted stock units issued pursuant to the Invacare Corporation 2013 Equity Compensation Plan that vest in full on August 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted pursuant to the Invacare Corporation 2013 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2019.
F2: Includes 5,020 previously reported restricted stock units issued pursuant to the Invacare Corporation 2013 Equity Compensation Plan that vest in full on August 15, 2018.
Option Care Health, Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,087 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 8,997 · Balance 21,087 F1: The reporting person received an award of restricted stock units on May 20, 2026, which vest in full on May 20, 2027. The number of restricted stock units granted was calculated to reflect $200,000 of value based on the closing price of the issuer's common stock on May 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an award of restricted stock units on May 20, 2026, which vest in full on May 20, 2027. The number of restricted stock units granted was calculated to reflect $200,000 of value based on the closing price of the issuer's common stock on May 20, 2026.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Hill-Rom Holdings, Inc.
Report date December 13, 2021 · Filed December 15, 2021
Section 16 reporting ended · disclosed 2021-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 1
1 source rowRow 1 · 2021-12-13 · Disposition to issuer · Disposed 14,039.759 · Balance 0 F1: Amount of securities beneficially owned at the end of the reporting period includes 718.759 shares held in the Hill-Rom Holdings, Inc. Employee Stock Purchase Plan. F2: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.76 · Expires 2028-12-03 | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-13 · Disposition to issuer · Disposed 10,272 · Balance 0 F3: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on December 3, 2019, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.11 · Expires 2029-11-06 | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-13 · Disposition to issuer · Disposed 15,491 · Balance 0 F4: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.14 · Expires 2030-11-11 | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-13 · Disposition to issuer · Disposed 17,935 · Balance 0 F5: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. |
| Performance-Based Restricted Stock Units (11/06/2019)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-13 · Disposition to issuer · Disposed 7,452 · Balance 0 F6: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F7: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level. |
| Performance-Based Restricted Stock Units (11/11/2020)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-13 · Disposition to issuer · Disposed 9,091 · Balance 0 F6: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F8: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level. |
| Restricted Stock Units (11/06/2019)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-13 · Disposition to issuer · Disposed 1,253 · Balance 0 F9: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F10: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. |
| Restricted Stock Units (11/11/2020)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-12-13 · Disposition to issuer · Disposed 3,026 · Balance 0 F9: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F11: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. |
| Restricted Stock Units (11/10/2021)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-12-13 · Disposition to issuer · Disposed 13,951 · Balance 0 F9: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F12: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Amount of securities beneficially owned at the end of the reporting period includes 718.759 shares held in the Hill-Rom Holdings, Inc. Employee Stock Purchase Plan.
F2: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock.
F3: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on December 3, 2019, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.
F4: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.
F5: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.
F6: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock.
F7: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level.
F8: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level.
F9: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock.
F10: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock.
F11: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock.
F12: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger.
Syneos Health, Inc.
Report date September 28, 2023 · Filed September 28, 2023
Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-09-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-28 · Disposition to issuer · Disposed 3,522 · Balance 4,863 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Row 2 · 2023-09-28 · Disposition to issuer · Disposed 4,863 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes.
F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals,
F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.
Turning Point Therapeutics, Inc.
Report date August 17, 2022 · Filed August 17, 2022
Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.59 · Expires 2031-03-30 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-17 · Disposition to issuer · Disposed 14,995 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2020 Filed Dec 7, 2020 16:01 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Tax withholdingCommon Stock | 820 | $95.79 | $78,547.80 |
DisclosureSEC source: 0000047518-20-000150 · wf-form4_160737489333642.xml · nonDerivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,868 F1 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. Common Stock incident to the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 16:01 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionCommon Stock | 2,616 | $95.79 | $250,586.64 |
DisclosureSEC source: 0000047518-20-000150 · wf-form4_160737489333642.xml · nonDerivative · entry 3 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 16:01 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Tax withholdingCommon Stock | 307 | $95.79 | $29,407.53 |
DisclosureSEC source: 0000047518-20-000150 · wf-form4_160737489333642.xml · nonDerivative · entry 2 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,072 F1 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. Common Stock incident to the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 16:01 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionCommon Stock | 980 | $95.79 | $93,874.20 |
DisclosureSEC source: 0000047518-20-000150 · wf-form4_160737489333642.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 16:02 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | GrantEmployee Stock Option (11/11/2020) · Derivative | 17,935 | $0.00 Strike: $94.14 | $0.00 |
DisclosureSEC source: 0000047518-20-000139 · wf-form4_160530134588114.xml · derivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,935 Underlying: Common Stock · 17,935 shares Expires 2030-11-11 F4 · derivative.exercise_date: Stock options vest 25% on each of November 11, 2021, 2022, 2023 and 2024. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 16:02 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | GrantRestricted Stock Units (11/11/2020) · Derivative | 4,546 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000047518-20-000139 · wf-form4_160530134588114.xml · derivative · entry 3 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,546 Underlying: Common Stock · 4,546 shares Expires 2023-11-12 F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Restricted stock units vest 34% on November 12, 2021 and 33% on November 12, 2022 and 2023. Restricted stock units are entitled to dividend equivalent rights which accrue on dividend record dates. F3 · derivative.expiration_date: Restricted stock units vest 34% on November 12, 2021 and 33% on November 12, 2022 and 2023. Restricted stock units are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 18:12 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionRestricted Stock Units (11/06/2019) · Derivative | 1,277 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000047518-20-000121 · wf-form4_160504995717096.xml · derivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,481.427 Underlying: Common Stock · 1,277 shares Expires 2022-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: Restricted stock units ("RSUs") were granted on November 6, 2019 and vested 34% on November 7, 2020; 33% will vest on November 7, 2021 and 2022, respectively. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F4 · derivative.expiration_date: Restricted stock units ("RSUs") were granted on November 6, 2019 and vested 34% on November 7, 2020; 33% will vest on November 7, 2021 and 2022, respectively. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 18:12 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Tax withholdingCommon Stock | 400 | $95.75 | $38,300.00 |
DisclosureSEC source: 0000047518-20-000121 · wf-form4_160504995717096.xml · nonDerivative · entry 2 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,399 F1 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. Common Stock incident to the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 18:12 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionCommon Stock | 1,277 | $95.75 | $122,272.75 |
DisclosureSEC source: 0000047518-20-000121 · wf-form4_160504995717096.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 16:15 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionRestricted Stock Units (12/03/2018) · Derivative | 2,671 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000047518-19-000108 · wf-form4_157566692473535.xml · derivative · entry 7 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,189.478 Underlying: Common Stock · 2,671 shares Expires 2021-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: Restricted stock units vest 34% on December 4, 2019 and 33% on December 4, 2020 and 2021. Restricted stock units are entitled to dividend equivalent rights which accrue on dividend record dates. F4 · derivative.expiration_date: Restricted stock units vest 34% on December 4, 2019 and 33% on December 4, 2020 and 2021. Restricted stock units are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 16:15 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionRestricted Stock Units (12/03/2018) LTI · Derivative | 1,002 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000047518-19-000108 · wf-form4_157566692473535.xml · derivative · entry 6 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946.184 Underlying: Common Stock · 1,002 shares Expires 2021-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: Restricted stock units vest 34% on December 4, 2019 and 33% on December 4, 2020 and 2021. Restricted stock units are entitled to dividend equivalent rights which accrue on dividend record dates. F4 · derivative.expiration_date: Restricted stock units vest 34% on December 4, 2019 and 33% on December 4, 2020 and 2021. Restricted stock units are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 16:15 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Tax withholdingCommon Stock | 837 | $106.53 | $89,165.61 |
DisclosureSEC source: 0000047518-19-000108 · wf-form4_157566692473535.xml · nonDerivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,522 F1 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. Common Stock incident to the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 16:15 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionCommon Stock | 2,671 | $106.53 | $284,541.63 |
DisclosureSEC source: 0000047518-19-000108 · wf-form4_157566692473535.xml · nonDerivative · entry 3 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 16:15 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Tax withholdingCommon Stock | 314 | $106.53 | $33,450.42 |
DisclosureSEC source: 0000047518-19-000108 · wf-form4_157566692473535.xml · nonDerivative · entry 2 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688 F1 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. Common Stock incident to the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 16:15 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionCommon Stock | 1,002 | $106.53 | $106,743.06 |
DisclosureSEC source: 0000047518-19-000108 · wf-form4_157566692473535.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2019 Filed Nov 7, 2019 18:56 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | GrantEmployee Stock Option (11/6/2019) · Derivative | 15,491 | $0.00 Strike: $103.11 | $0.00 |
DisclosureSEC source: 0000047518-19-000075 · wf-form4_157317100425954.xml · derivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,491 Underlying: Common Stock · 15,491 shares Expires 2029-11-06 F4 · derivative.exercise_date: Options vest 25% on each of November 6, 2020, 2021, 2022 and 2023. Read SEC document |
| November 06, 2019 Filed Nov 7, 2019 18:56 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | GrantRestricted Stock Units (11/06/2019) · Derivative | 3,726 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000047518-19-000075 · wf-form4_157317100425954.xml · derivative · entry 3 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,726 Underlying: Common Stock · 3,726 shares Expires 2022-11-07 F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Restricted stock units vest 34% on November 7, 2020 and 33% on November 7, 2021 and 2022. Restricted stock units are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:08 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | GrantRestricted Stock Units (12/03/2018) LTI · Derivative | 2,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000047518-18-000148 · wf-form4_154413049512700.xml · derivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,924 Underlying: Common Stock · 2,924 shares Expires 2021-12-04 F2 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · shares: RSUs are entitled to dividend equivalent rights which accrue on dividend record dates. F4 · derivative.exercise_date: RSUs vest 34% on December 4, 2019 and 33% on December 4, 2020 and 2021. F4 · derivative.expiration_date: RSUs vest 34% on December 4, 2019 and 33% on December 4, 2020 and 2021. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:08 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | GrantRestricted Stock Units (12/03/2018) · Derivative | 7,796 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000047518-18-000148 · wf-form4_154413049512700.xml · derivative · entry 3 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,796 Underlying: Common Stock · 7,796 shares Expires 2021-12-04 F2 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · shares: RSUs are entitled to dividend equivalent rights which accrue on dividend record dates. F4 · derivative.exercise_date: RSUs vest 34% on December 4, 2019 and 33% on December 4, 2020 and 2021. F4 · derivative.expiration_date: RSUs vest 34% on December 4, 2019 and 33% on December 4, 2020 and 2021. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:08 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | GrantEmployee Stock Option (12/03/2018) · Derivative | 10,272 | $0.00 Strike: $98.76 | $0.00 |
DisclosureSEC source: 0000047518-18-000148 · wf-form4_154413049512700.xml · derivative · entry 2 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,272 Underlying: Common Stock · 10,272 shares Expires 2028-12-03 F1 · derivative.exercise_date: Stock options vest 25% on each of December 3, 2019, 2020, 2021 and 2022. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 17:39 UTC | INVACARE HOLDINGS Corp IVC · Entity 86444 | GrantCommon Shares | 6,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020947 · doc4.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,728 F1 · shares: Restricted stock units granted pursuant to the Invacare Corporation 2013 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2019. F2 · balance_after: Includes 5,020 previously reported restricted stock units issued pursuant to the Invacare Corporation 2013 Equity Compensation Plan that vest in full on August 15, 2018. Read SEC document |
| August 18, 2017 Filed Aug 21, 2017 11:59 UTC | INVACARE HOLDINGS Corp IVC · Entity 86444 | GrantCommon Shares | 5,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049682 · doc4.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,020 F1 · shares: Restricted stock units granted pursuant to the Invacare Corporation 2013 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on August 15, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.